Josef Penninger, University of Toronto

Research

Biomedical Research Development Of New Therapeutics Biobanking Knowledge Translation Long Covid Mechanism Of Disease National Network Patient Engagement

Latest papers

Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice.
The Journal of clinical investigation · 2010

All 1 publications

Latest funding

Long COVID Web: Pan-Canadian Post-COVID Condition Research Network
CIHR · 2022 · Principal investigator
$19,999,614
COVID-19 Variant Supplement - Molecular and cellular therapies against COVID-19 using angiotensin-converting enzyme 2 (ACE2)
CIHR · 2021 · Principal investigator
$50,000
Sex as a Biological Variable Supplement - Molecular and cellular therapies against COVID-19 using angiotensin-converting enzyme 2 (ACE2)
CIHR · 2020 · Principal investigator
$50,000

All 5 grants and awards

1 publications.

01

Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice.

Molyneux SD, Di Grappa MA, Beristain AG, McKee TD, Wai DH, Paderova J, Kashyap M, Hu P, Maiuri T, Narala SR, Stambolic V, Squire J, Penninger J, Sanchez O, Triche TJ, Wood GA, Kirschner LS, Khokha R

The Journal of clinical investigation2010

DOI: 10.1172/jci42391 PMID: 20697156

Long COVID Web: Pan-Canadian Post-COVID Condition Research Network

Principal investigatorCIHR2022Operating Grant: Canadian Post COVID-19 Condition Research Network

Principal investigators: Cheung, Angela M; Goulding, Susie E; Graves, Donna Lorraine; Archambault, Patrick; Awadalla, Philip; Bakal, Jeffrey A; Bhéreur, Anne; Brotto, Lori Anne; Busse, Jason W; Cameron, Jill I; Churchill, Katie; Crawley, Angela M; Décary, Simon; Durand, Madeleine; Falcone, Emilia L; Fowler, Robert A; Gommerman, Jennifer L; Graham, Kathryn E; Graham, Simon J; Groot, Gary; Gross, Douglas P; Guyatt, Gordon H; Halas, Gayle; Ho, Chester; Hohl, Corinne M; Holroyd, Brian R; Janjua, Naveed Z; Johnson, Pauline; Juando Prats, Clara; Kashuba, Sherri; Katz, Alan; Kho, Michelle E; Lam, Grace Y; Lamontagne, Francois; Langlois, Marc-Andre; Lavis, John N; Law, Susan K; LeBlanc, Annie; Levin, Adeera; Liu-Ambrose, Teresa Y; Liu, Peter P; Lix, Lisa M; Mandhane, Piush; Mann, Balraj; McGrail, Kimberlyn M; McNagny, Kelly M; Miciak, Maxi A; Mishra, Sharmistha; Muhajarine, Nazeem; Mukherjee, Manali; Mushquash, Christopher J; Nacul, Luis; O'Brien, Kelly K; Osgood, Nathaniel D; Papathanasoglou, Elisavet; Penninger, Josef; Piche, Alain; Pinto, Andrew D; Quinn, Kieran L; Rafferty, Ellen; Raj, Satish R; Razak, Fahad; Russell, James A; Sander, Beate H; Sekuler, Allison B; Soares, Claudio D; Tailfeathers, Esther; Tomlinson, George A; Tricco, Andrea C; Valdez, Yanet; Verma, Amol; Vohra, Sunita; Walmsley, Sharon L; Walsh, Jillian; Weeks, Laura C; Williams, Kienan; Wu, Jianhong; Yeung, Rae S

Keywords: Biobanking; Knowledge Translation; Long Covid; Mechanism Of Disease; National Network; Patient Engagement; Patient Registries; Post-Covid Condition; Research Communications; Social Determinants Of Health

$19,999,614

COVID-19 Variant Supplement - Molecular and cellular therapies against COVID-19 using angiotensin-converting enzyme 2 (ACE2)

Principal investigatorCIHR2021Operating Grant: SARS-CoV-2 variants supplement stream 1

Principal investigators: Zhang, Haibo; Mirazimi, Ali; Penninger, Josef; Slutsky, Arthur S

Keywords: Biomedical Research; Development Of New Therapeutics

$50,000

Sex as a Biological Variable Supplement - Molecular and cellular therapies against COVID-19 using angiotensin-converting enzyme 2 (ACE2)

Principal investigatorCIHR2020Op Grant: Sex as a Biological Variable Supplement: COVID-19 Rapid Research FO

Principal investigators: Zhang, Haibo; Mirazimi, Ali; Penninger, Josef; Slutsky, Arthur S

Keywords: Biomedical Research; Development Of New Therapeutics

$50,000

Molecular and cellular therapies against COVID-19 using angiotensin-converting enzyme 2 (ACE2)

Principal investigatorCIHR2020Operating Grant: COVID-19 - Therapeutics

Principal investigators: Zhang, Haibo; Mirazimi, Ali; Penninger, Josef; Slutsky, Arthur S

Keywords: Biomedical Research; Development Of New Therapeutics

$1,000,000

Canadian Network for Vaccines and Immunotherapeutics of Cancer and Chronic Viral Diseases (CANVAC) (2006 Renewal Competition)

Co-investigatorNSERC2006Networks of Centres of Excellence

Principal investigators: Sekaly, RafickPierre

$3,999,490

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Frequent collaborators

Biostatistics Division
Cancer Research
Research
Other

Co-authors at University of Toronto, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.

Pingzhao Hu

Biostatistics Division

1 shared papers, latest 2010

Rama Khokha

Cancer Research

1 shared papers, latest 2010

Vuk Stambolic

Research

1 shared papers, latest 2010

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Mention their CIHR grant from 2022

Subject: Prospective PhD student: Biomedical Research Dear Professor Penninger, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice." (2010), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Long COVID Web: Pan-Canadian Post-COVID Condition Research Network" (2022), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]